CN104083444A - Anti-myocardial ischemia pharmaceutical composition and use thereof - Google Patents
Anti-myocardial ischemia pharmaceutical composition and use thereof Download PDFInfo
- Publication number
- CN104083444A CN104083444A CN201410365140.9A CN201410365140A CN104083444A CN 104083444 A CN104083444 A CN 104083444A CN 201410365140 A CN201410365140 A CN 201410365140A CN 104083444 A CN104083444 A CN 104083444A
- Authority
- CN
- China
- Prior art keywords
- myocardial ischemia
- pharmaceutical composition
- extract
- spun gold
- gold rattan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 44
- 235000012950 rattan cane Nutrition 0.000 claims description 43
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 42
- 239000010931 gold Substances 0.000 claims description 42
- 229910052737 gold Inorganic materials 0.000 claims description 42
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 241000345998 Calamus manan Species 0.000 claims 6
- 238000011282 treatment Methods 0.000 abstract description 7
- 241000207840 Jasminum Species 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000002107 myocardial effect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 3
- 244000145591 rattan cane Species 0.000 description 37
- 241000700159 Rattus Species 0.000 description 24
- 210000004165 myocardium Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- 208000003890 Coronary Vasospasm Diseases 0.000 description 2
- 241000207834 Oleaceae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000011634 coronary artery vasospasm Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000006479 Cyme Species 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- -1 nitric acid lipid Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an anti-myocardial ischemia pharmaceutical composition and a use thereof. The pharmaceutical composition is prepared from active ingredients and pharmaceutically acceptable auxiliaries; the active ingredients include a jasminum cinnamomifolium extract. The jasminum cinnamomifolium extract of the pharmaceutical composition serves as the active ingredient and is capable of improving the heart ST segment and T waves of an acute myocardial ischemia patient and also capable of protecting the myocardial cells from being damaged by radical oxidation and enhancing the energy supply to the body, so that the treatment purpose of anti-myocardial ischemia is achieved.
Description
Technical field
The invention belongs to Chinese crude drug extractive technique field, in particular to a kind of medical composition and its use resisting myocardial ischemia.
Background technology
Myocardial ischemia refers to that the hemoperfusion of heart reduces, and causes the oxygen supply of heart to reduce, and energy metabolism of myocardial is undesired, can not support a kind of pathological state of the normal work of heart.Interrelated data demonstration, myocardial ischemia mostly occurred after 40 years old, and average prevalence is about 6.49%.Along with the raising of living standards of the people, myocardial ischemia is in the prevalence of China the trend rising year by year at present, and morbidity crowd rejuvenation trend is obvious.Myocardial ischemia is also one of disease kind that mortality rate is the highest, is common in acute sudden death, myocardial infarction etc.Modern medicine is thought, the common reason of myocardial ischemia is coronary atherosclerosis, secondly also has inflammation (rheumatic, syphilis, mucocutaneous lymphnode syndrome and thromboangitis obliterans etc.), spasm, thromboembolism, connective tissue disease, wound and congenital malformation etc. multiple.
Doctor trained in Western medicine has Drug therapy to the Therapeutic Method of primary disease, and as antiplatelet drug, receptor blocking agent, calcium ion antagonist, statins, nitric acid lipid drug, thrombolytic class medicine etc., its curative effect is all not ideal, only only alleviate, and side effect is larger.In view of western medical treatment is limited to, takes stopgap measures and be difficult to effect a permanent cure, even if interventional therapy and operative treatment winner comparatively, be also difficult to multiple to patient with healthy physique, the Chinese medicine of therefore finding many target treatments seems particularly urgent.
Spun gold Calamus is in climbing shrub, high 1-4m.Herb unit hair.Cylindrical or the tool rill of sprig, footpath 1-2mm.Leaf is to life, single leaf; The long 4-10mm of petiole, reverses, and has joint; Blade papery or thin keratin, oval or narrow ellipse, rare by aciculiform, long 5-10.5cm, wide 1.5-4.5cm, the sharp point of tip is point extremely gradually, base portion wedge shape or circle, leaf margin warp, base goes out 5, arteries and veins, and 1 pair, outside is not obvious, extends upward through top, and is connected with transverse vein.Flower Dan Sheng, or be umbrella cyme, top is raw or axil is raw, has colored 1-5 piece; Inflorescence is without stalk or the long 0.2-2cm of stalk; Bract is linear, long 2-4mm; Bennet is elongated, and long 1.4-2.5cm makes progress cumulative thick; Calyx pipe range 2-3mm, 5 pieces of slivers, sharp triangle, long 1-2mm; Corolla white, high foot dish shape, corolla pipe range 0.9-1.3cm, footpath 1-2mm, sliver 9-11 piece, lanceolar, long 1.1-2cm, wide 1.5-3mm, tip is point gradually.Fruit is spherical or oval, long 1-1.5cm, and footpath 0.8-1.5cm, is black.The florescence 3-9 month, the fruit phase 5-11 month.Be born in woods or sand ground.Be distributed in Hainan, Yunnan.
At present, spun gold rattan as Chinese crude drug be in the news there is heat-clearing and toxic substances removing, effect that synthetism is cured the wound, be mainly used in controlling laryngopharynx swelling and pain, pathopyretic ulcer, fracture and traumatic hemorrhage, there is no bibliographical information spun gold rattan or its extract and have and strengthen the biological activity that acute myocardial ischemia patient cardiac muscle energy supply or anti-myocardial are subject to Free radicals injury.
Summary of the invention
The object of the invention is to by secret prescription handed down in the family from generation to generation is furtherd investigate, thereby a kind of pharmaceutical composition resisting myocardial ischemia is provided, a kind of pharmaceutical composition of anti-acute myocardial ischemia is especially provided.This spun gold rattan extract can be developed into the pharmaceutical preparation of the disease due to the myocardial ischemia such as treatment coronary heart diseases and angina pectoris.
Particularly, the object of the invention is to adopt following technical scheme to realize:
The pharmaceutical composition resisting myocardial ischemia, is prepared from by acceptable adjuvant on active component and pharmaceutics, it is characterized in that, described active component comprises spun gold rattan extract.
Preferably, the pharmaceutical composition resisting myocardial ischemia as mentioned above, wherein, described spun gold rattan extract is prepared from by the following method: depletion silk rattan raw material, add aqueous sodium carbonate reflux, extract,, and extracting solution regulates pH=2.8-3.2 with hydrochloric acid, standing, filter, get precipitation and be dried, obtain spun gold rattan extract.
Further preferably, the pharmaceutical composition resisting myocardial ischemia as mentioned above, wherein, the concentration of described aqueous sodium carbonate is 3%-10%.
Again further preferably, the pharmaceutical composition resisting myocardial ischemia as mentioned above, wherein, the concentration of described aqueous sodium carbonate is 4%-7%.
Again further preferably, the pharmaceutical composition resisting myocardial ischemia as mentioned above, wherein, the 8-15 that the consumption of described aqueous sodium carbonate is raw material weight is doubly.
Further preferably, the pharmaceutical composition resisting myocardial ischemia as mentioned above, wherein, the number of times of described reflux, extract, is 1-4 time, boils 2-4h at every turn.
Further preferably, the pharmaceutical composition resisting myocardial ischemia as mentioned above, wherein, described extracting solution regulates pH=3.0 by acid solution.
Further preferably, the pharmaceutical composition resisting myocardial ischemia as mentioned above, wherein, the time of described standing step is 4-24h.
It should be noted that the tender leaf of the spun gold rattan raw material choose Oleaceae plants Jasminum cinnamomi folium kobuski. Jasminum cinnamomifolium Kobuski that the present invention adopts when the described spun gold rattan extract of preparation.The dry product drying can be selected, also fresh wet product can be selected.
The inventor causes that by lumbar injection Pit coronary vasospasm is to copy Model Rats with Acute Myocardial Ischemia.Pit extracts the material obtaining from animal hypophysis cerebri, contains vassopressin (vassopressin) and oxytocin, and vassopressin can directly make blood vessel, particularly blood capillary and small artery shrink, thereby can make coronary vasospasm, contraction make myocardial ischemia-anoxemia.Therefore, the Model Rats with Acute Myocardial Ischemia that the present invention copies occurs that abnormal electrocardiographic pattern changes, and is mainly reflected in ST section, T ripple is abnormal.By giving spun gold rattan extract, carry out therapeutic intervention discovery, spun gold rattan extract can improve rat model electrocardiographic abnormality situation, to play protection Myocardial Effects.In addition, in acute myocardial ischemia process, ultra-oxygen anion free radical (O
2 -) a large amount of formation and the increase of lipid peroxidation be one of main pathological process of cell injury.SOD is extensively present in organism and the closely-related protein of cell oxygen metabolism, highly in specific manner the catalysis O harmful to body
2 -dismutation reaction, and get rid of O
2 -infringement to body cell, tissue, the damage of antagonism ischemic hypoxia disease, hypoxic-ischemic again perfused tissue damage have important protective effect.MDA is the stable metabolite of lipid peroxidation, measure MDA content can reflecting myocardium tissue in O
2 -content and the lipid peroxidation degree of initiation, indirectly reflect that cell is subject to the degree of Free radicals injury.The present invention shows by above-mentioned experimental study, and it is active that spun gold rattan extract can significantly strengthen model rat heart muscle SOD, reduces MDA content, thus protection damaged myocardium.Moreover ATP is a kind of coenzyme, participate in the metabolism such as body protein, fat, sugar, nucleic acid, nucleotide, be again the main source of human body energy, its Developmental and Metabolic Disorder can reflect that body energy supply is abnormal.The present invention shows by above-mentioned experimental study, and spun gold rattan extract can significantly strengthen model rat heart muscle ATP content, thereby guarantees that the energy supply of damaged myocardium is sufficient.In sum, spun gold rattan extract can play a protective role to Model of Acute Myocardial Ischemia rat, and it is machine-processed and improve heart ST section, T ripple and antioxidation, and enhancing body energy supply is relevant.
Based on above-mentioned result of study, another object of the present invention is to provide a kind of pharmaceutical applications, that is: the purposes in the medicine that above-mentioned spun gold rattan extract resists myocardial ischemia in preparation.Or: above-mentioned spun gold rattan extract improves the purposes in the medicine of acute myocardial ischemia patient electrocardiographic abnormality in preparation; The purposes of above-mentioned spun gold rattan extract in the medicine of preparation enhancing acute myocardial ischemia patient cardiac muscle energy supply; The purposes of above-mentioned spun gold rattan extract in preparing anti-myocardial and be subject to the medicine of Free radicals injury.
Compared with prior art, the pharmaceutical composition the present invention relates to is prepared from as unique raw material by spun gold rattan, contained spun gold rattan extract can improve acute myocardial ischemia patient's heart ST section, T ripple as active component, can be subject to Free radicals injury by anti-myocardial simultaneously, enhancing body energy supply, thus reach the therapeutic purposes of the myocardial ischemia diseases such as resisting coronary heart disease, angina pectoris.
The specific embodiment
Be below Preparation Example and the effect test example of spun gold rattan extract of the present invention, the present invention will be further described and explanation.It should be noted that the dry tender leaf of the spun gold rattan raw material choose Oleaceae plants Jasminum cinnamomi folium kobuski. Jasminum cinnamomifolium Kobuski that following examples adopt when the described spun gold rattan extract of preparation.
The preparation of embodiment 1 spun gold rattan extract
Take dry spun gold rattan 850g, roguing, adds 10L mass percentage concentration and is 5% sodium carbonate liquor, soak 40min, reflux, extract, 2 times is boiled 3h at every turn, filter, merging filtrate, regulates filtrate pH=3.0 with concentrated hydrochloric acid, room temperature standing over night, filters, and gets precipitation, dry, pulverize, cross 100 mesh sieves, obtain spun gold rattan extract dry powder.
The affect experimental study of embodiment 2 spun gold rattan extract on Model of Acute Myocardial Ischemia rat
60 of clean level SD rats, male, body weight 150～180g, experiment is divided into following five groups, be Normal group (wait and hold normal saline), model control group (wait and hold normal saline), sorbide nitrate (15mg/kg) and spun gold rattan extract high and low dose (spun gold rattan extract dry powder 180, the 60mg/kg of embodiment 1 preparation) group, 12 every group.Gastric infusion, every day 1 time, continuous 15d, 1h after last administration, except Normal group, all the other respectively organize lumbar injection Pit (20U/kg) to copy Acute Myocardial Ischemia Rats model.
After last administration 1 h, lumbar injection 3% pentobarbital sodium (1mL/kg) anesthesia rats in normal control group, back of the body position is fixing, and the needle electrode of polygraph inserts respectively subcutaneous, and first Continuous Observation also records one section of normal ECG; After duplicating model, detect all the other and respectively organize Rat Ecg ST section and T ripple.Then put to death rat, get and respectively organize rat cardiac ventricular flesh, homogenate in frozen water, the centrifugal 5min of l000r/min, gets supernatant as sample.With TBA method thought-read flesh MDA content, with pyrogallol method, survey SOD active.Separately get and respectively organize rat cardiac ventricular flesh and shred, the cooling lower pulverize of nitrogen, adds 1 mL acetone immediately after weighing, and room temperature is placed 15min, and in 90 ℃ of water-baths, about 4min volatilizes acetone, adds 5 mL 2mmol/L MgSO
4, cooling after boiling water boiling 15min, the centrifugal 10min of 1000r/min, gets supernatant as sample, by the content of biloluminescence method working sample ATP.
The demonstration of detecting ECG result, with Normal group comparison, model group Rat Ecg ST section is obviously raised, and T wave height JIANMING is aobvious, shows that Model of Acute Myocardial Ischemia copies successfully; Spun gold rattan extract high dose group Rat Ecg ST section is slightly raised, and low dose group Rat Ecg ST section is obviously raised, and shows that high dose spun gold rattan extract is improved effect to rat model ECG ST section.
The impact of spun gold rattan extract active on rat model SOD of heart tissue in MDA content is in Table l.Result of the test by table 1 can find out, with Normal group comparison, model control group rat heart muscle SOD activity significantly weakens, MDA content significantly raise (
p< 0.01), show that rat heart muscle oxidation resistance weakens.With model control group comparison, spun gold rattan extract high and low dose group rat heart muscle SOD is active significantly to be strengthened (
p< 0.01), MDA content significantly reduce (
p< 0.01 or
p< 0.05).This result shows that spun gold rattan extract has certain antioxidation, and is dose-effect relationship.
Table l respectively organizes rat heart muscle SOD activity and the comparison of MDA content
Model control group and Normal group comparison,
● p< 0.05,
● ● p< 0.01;
Treatment group and model control group comparison,
★ p< 0.05,
★ ★ p< 0.01.
Spun gold rattan extract on the impact of rat model myocardium ATP content in Table 2.Result of the test by table 2 can find out, with Normal group comparison, model control group rat heart muscle ATP content significantly reduce (
p< 0.01), show that rat heart muscle energy supply is abnormal.With model group comparison, spun gold rattan extract high and low dose group rat heart muscle ATP content significantly raise (
p< 0.01 or
p< 0.05).This result shows that spun gold rattan extract has the abnormal effect of the myocardium energy supply of certain improvement, and is dose-effect relationship.
Table 2 is respectively organized the comparison of rat heart muscle ATP content
Model control group and Normal group comparison,
● p< 0.05,
● ● p< 0.01;
Treatment group and model control group comparison,
★ p< 0.05,
★ ★ p< 0.01.
Claims (10)
1. the pharmaceutical composition resisting myocardial ischemia, is prepared from by acceptable adjuvant on active component and pharmaceutics, it is characterized in that: described active component comprises spun gold rattan extract.
2. the pharmaceutical composition resisting myocardial ischemia according to claim 1, it is characterized in that: described spun gold rattan extract is prepared from by the following method: depletion silk rattan raw material, add aqueous sodium carbonate reflux, extract,, extracting solution regulates pH=2.8-3.2 with hydrochloric acid, standing, filter, get precipitation and be dried, obtain spun gold rattan extract.
3. the pharmaceutical composition resisting myocardial ischemia according to claim 2, is characterized in that: the concentration of described aqueous sodium carbonate is 3%-10%.
4. the pharmaceutical composition resisting myocardial ischemia according to claim 3, is characterized in that: the concentration of described aqueous sodium carbonate is 4%-7%.
5. the pharmaceutical composition resisting myocardial ischemia according to claim 4, is characterized in that: the 8-15 that the consumption of described aqueous sodium carbonate is raw material weight doubly.
6. the pharmaceutical composition resisting myocardial ischemia according to claim 2, is characterized in that: the number of times of described reflux, extract, is 1-4 time, boils 2-4h at every turn.
7. the pharmaceutical composition resisting myocardial ischemia according to claim 2, is characterized in that: described extracting solution regulates pH=3.0 by acid solution.
8. the pharmaceutical composition resisting myocardial ischemia according to claim 2, is characterized in that: the time of described standing step is 4-24h.
9. the purposes in the medicine that spun gold rattan extract claimed in claim 1 resists myocardial ischemia in preparation.
10. the purposes of spun gold rattan extract claimed in claim 1 in preparing anti-myocardial and be subject to the medicine of Free radicals injury.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610075451.0A CN105596432A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine resisting free radical oxidation damage of cardiac muscle cells |
| CN201410365140.9A CN104083444B (en) | 2014-07-29 | 2014-07-29 | A kind of medical composition and its use resisted myocardial ischemia |
| CN201610075413.5A CN105596431A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine improving electrocardiographic abnormality of patient suffering from acute myocardial ischemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410365140.9A CN104083444B (en) | 2014-07-29 | 2014-07-29 | A kind of medical composition and its use resisted myocardial ischemia |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610075413.5A Division CN105596431A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine improving electrocardiographic abnormality of patient suffering from acute myocardial ischemia |
| CN201610075395.0A Division CN105663252A (en) | 2014-07-29 | 2014-07-29 | Application of Jasminum cinnamomifolium Kobuski extract in preparation of anti-myocardial ischemia medicine |
| CN201610075451.0A Division CN105596432A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine resisting free radical oxidation damage of cardiac muscle cells |
| CN201610075448.9A Division CN105708905A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium extract in preparing drug for enhancing cardiac muscle energy supply of patient with acute myocardial ischemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104083444A true CN104083444A (en) | 2014-10-08 |
| CN104083444B CN104083444B (en) | 2016-04-13 |
Family
ID=51631272
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610075413.5A Withdrawn CN105596431A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine improving electrocardiographic abnormality of patient suffering from acute myocardial ischemia |
| CN201410365140.9A Active CN104083444B (en) | 2014-07-29 | 2014-07-29 | A kind of medical composition and its use resisted myocardial ischemia |
| CN201610075451.0A Withdrawn CN105596432A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine resisting free radical oxidation damage of cardiac muscle cells |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610075413.5A Withdrawn CN105596431A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine improving electrocardiographic abnormality of patient suffering from acute myocardial ischemia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610075451.0A Withdrawn CN105596432A (en) | 2014-07-29 | 2014-07-29 | Application of jasminum cinnamomifolium kobuski extract in preparation of medicine resisting free radical oxidation damage of cardiac muscle cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN105596431A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050142229A1 (en) * | 2003-12-29 | 2005-06-30 | Jiao Gong | Pharmaceutical activity and manufacturing method of the four-plant-derived coronary blood flow enhancing agent |
| CN1813902A (en) * | 2005-12-02 | 2006-08-09 | 蓝子花 | Salacia medicinal liquor for dispelling wetness-evil and stopping pain |
-
2014
- 2014-07-29 CN CN201610075413.5A patent/CN105596431A/en not_active Withdrawn
- 2014-07-29 CN CN201410365140.9A patent/CN104083444B/en active Active
- 2014-07-29 CN CN201610075451.0A patent/CN105596432A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050142229A1 (en) * | 2003-12-29 | 2005-06-30 | Jiao Gong | Pharmaceutical activity and manufacturing method of the four-plant-derived coronary blood flow enhancing agent |
| CN1813902A (en) * | 2005-12-02 | 2006-08-09 | 蓝子花 | Salacia medicinal liquor for dispelling wetness-evil and stopping pain |
Non-Patent Citations (2)
| Title |
|---|
| 党金玲等: "三亚大茅村药用植物资源调查研究", 《时珍国医国药》 * |
| 国家中医药管理局《中华本草》编委会编: "《中华本草6》", 31 December 1999, 上海科学技术出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104083444B (en) | 2016-04-13 |
| CN105596432A (en) | 2016-05-25 |
| CN105596431A (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446385B (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
| CN102302552A (en) | Capsules for treating arrhythmia and preparation method thereof | |
| CN103156842B (en) | Novel application of Arctigenin in preparation of anti-arrhythmia medicine | |
| CN107496573A (en) | Application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease | |
| CN104083444B (en) | A kind of medical composition and its use resisted myocardial ischemia | |
| CN103784934B (en) | A kind of pharmaceutical composition and application thereof preventing and treating acute myocardial infarction | |
| CN1285334C (en) | Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell | |
| CN104970223A (en) | Compound feed for cattle and preparation method of compound feed | |
| CN105708905A (en) | Application of jasminum cinnamomifolium extract in preparing drug for enhancing cardiac muscle energy supply of patient with acute myocardial ischemia | |
| CN105663252A (en) | Application of Jasminum cinnamomifolium Kobuski extract in preparation of anti-myocardial ischemia medicine | |
| CN100430079C (en) | Chinese medicine for treating heart disease | |
| CN104256618B (en) | A kind of hypoglycemic food, health products or pharmaceutical composition | |
| CN103549072B (en) | Vital energy-benefiting brain-boosting tea and preparation method thereof | |
| CN104622987B (en) | A kind of pharmaceutical composition for treating chronic hepatitis liver cirrhosis and application | |
| CN101830878A (en) | Polymethoxyflavonoids (PMFs) and derivative as medicaments for preventing and treating atrial fibrillation (AF) and using method | |
| CN107693682A (en) | A kind of anaesthetic for treating sub- agate disease and preparation method thereof | |
| CN110841037B (en) | Traditional Chinese medicine medicament for treating circadian rhythm disorder sleep disorder and preparation method thereof | |
| Tai et al. | Sinomenine | |
| CN105641016A (en) | Pharmaceutical composition for treating coronary heart disease | |
| CN102973698B (en) | Traditional Chinese medicine preparation for treating hyperplasia of mammary glands | |
| CN1135996C (en) | Chinese medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN101491594A (en) | Soft-capsules for treating bronchitis and preparation method thereof | |
| CN104095845A (en) | Pharmaceutical composition for alleviating skin itch and application thereof | |
| CN104523869B (en) | It is a kind of to treat chronic hepatitis, the Chinese medicine composition and preparation method thereof of hepatic sclerosis | |
| CN117942323A (en) | Application of resveratrol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Bian Weishi Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160303 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266000, Optics Valley Software Park, second floors Applicant after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Applicant before: Wang Xueyan |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Bian Weishi Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160317 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266000, Optics Valley Software Park, second floors Applicant after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Applicant after: Bian Weishi Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Applicant before: Wang Xueyan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160713 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266000, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Patentee before: Bian Weishi |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Bian Weishi Inventor after: Chen Xiaoli Inventor after: Ding Ximing Inventor after: Lu Liqin Inventor after: Zhang Wei Inventor after: Yao Fangcheng Inventor after: Zhang Jirong Inventor after: You Fuli Inventor before: Bian Weishi |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170524 Address after: 226200 No. 46 Industrial Park, Nanyang Town, Nantong, Jiangsu, Qidong Patentee after: Qidong planting valve factory Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. |
|
| TR01 | Transfer of patent right |